Author: Pharma Machines

Roadmap to induce agility to pharma industry Agile Transformation Plan: Pharma companies need a systematic agility culture percolating from the

Facts & Figures India’s pharmaceutical industry is expected to expand at a compound annual growth rate (CAGR) of 22.4% in

PharmaTechnologyindex.com Pvt Ltd has successfully organized ten events including three at Indore, four at Ahmedabad and three events at Chandigarh.

Business Seminar A Seminar on “Business & Investment Opportunity in Ethiopia Specially in Pharma & Healthcare Sector” was organised on

After successful deliverance of the past nine events including three at Indore, three at Ahmedabad and three at Chandigarh, the10th

Because of their design, foam compression dock seals can restrict forklift access to the trailer. This happens as foam and

It may seem like a small issue, but each little gap you see around a parked trailer at the loading

Eminence Business Media organized “Pharma Authors Roundtable” on January 22nd, 2020 at Hotel JW Marriott, Mumbai, inviting all the young

The event also witnessed highly interactive sessions like working tables where delegates were masters of their own sessions while Mr.

Eminence Business Media’s 3rd Annual Pharma Project & Portfolio Management Summit 2020 successfully concluded on January 23rd & 24th, 2020

Over 45,000 visitors, 1,600+ exhibitors from 44 countries CPhI & P-MEC India 2019 – organised by Informa Markets – recently

‘We do discuss with people, we do interact with people’ “I frankly disagree when anybody says that we are not

Emerging markets will become increasingly important’ “It’s a very old story in the Indian pharma that the generics industry is

Creating an Agile Environment to Support Sustainable Growth The panel discussion at Eminence Business Media’s 3rd Annual Pharma Project &

Documentation and control strategy Filing expectations for new drugs Risk assessment for elemental impurities – (Summation option). Contribution of components

Potential sources of elemental impurities Elemental impurities that are unintentionally added and are potentially present in the drug substance, water

ELEMENTAL IMPURITIES The presence of elemental impurities in drug products can potentially have adverse health effects. Limits have been established

NDMA/NDME: Regulatory Perspective & Lesson Learned Case Study: What’s gone wrong in Valsartan? Valsartan is an angiotensin II receptor blocker

Control Strategy A control strategy is a planned set of controls derived from current product and process understanding that assures

(Q)SAR Systems A (Q)SAR (Quantitative structure–activity relationship) model can estimate the relationship between the structure of chemical substances and another

Acceptable Intake Treatment duration needs to be considered for applying acceptable intake. Treatment duration should be located in RLD label.

Industry & Regulatory Perspectives   Based on the presentation by Dr. Atul Awasthi, Director – GTS MSAT AS, Pfizer, at